Use of global coagulation assays to predict spontaneous major bleeding in chronic kidney disease patients


Rowena Brook, M.B.B.S.
Northern Health
Melbourne, Australia

Chronic kidney disease is associated with increased bleeding and cardiovascular risks in which management involves antiplatelets and/or anticoagulation. Currently, there are no routine blood tests to predict bleeding risk. In this presentation, Rowena Brook, M.B.B.S., discusses the team’s aims of evaluating the use of global coagulation assays (GCAs) in predicting risks of spontaneous major bleeding in CKD. This observational pilot study discusses the results from 87 patients. GCAs were performed on platelet-poor plasma, in particular calibrated automated thrombogram and overall hemostatic potential, which demonstrated association with spontaneous major bleeding in patients with CKD despite traditional surrogate markers not being predictive.

Previous Article Thrombosis survivor Robyne Toseland shares her story: “It felt as though an elephant was sitting on my chest”
Next Article 30 years later: ISTH’s first president from the Asian-Pacific region, Hidehiko Saito, reflects on his term